ABSTRACT
Spleen weight, the number of spleen mononuclear cells, and their phagocytic activity in groups of Babesia rodhaini-infected mice treated with diminazene diaceturate and clindamycin increased significantly in the early stage of treatment, and then decreased in the final stage of treatment to approximately the pre-infection level. The number of F4/80-positive macrophages and their oxidative activity per mean whole-spleen weight also increased significantly during the course of treatment in comparison with the untreated group. The increases in the clindamycin-treated group were more prominent than those in the group treated with diminazene diaceturate, suggesting the effectiveness of clindamycin therapy for murine babesiosis.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Babesia , Babesiosis/veterinary , Clindamycin/therapeutic use , Diminazene/analogs & derivatives , Macrophages/drug effects , Rodent Diseases/drug therapy , Animals , Antiprotozoal Agents/therapeutic use , Babesiosis/drug therapy , Babesiosis/parasitology , Diminazene/therapeutic use , Female , Hematocrit/veterinary , Macrophages/immunology , Macrophages/metabolism , Mice , Mice, Inbred BALB C , Organ Size/drug effects , Oxygen/metabolism , Parasitemia/drug therapy , Parasitemia/veterinary , Phagocytosis/drug effects , Rodent Diseases/parasitology , Spleen/cytology , Spleen/drug effectsABSTRACT
In order to identify the alternative effective chemotherapeutic agents for murine babesiosis, some selected drugs were examined for their efficacy against protozoan infection in the mouse-Babesia rodhaini (B. rodhaini) model. Clindamycin was not completely effective for elimination of parasites in a dose of 50 mg or 100 mg/kg BW/day b.i.d. but effective to prolong the life span of hosts, while it completely cured B. rodhaini infections in a dose of 200 mg. On the other hand, a double therapy consisting of 2 treatments with 100 mg clindamycin and 100 mg clindamycin and with 100 mg clindamycin and 100 mg tetracycline; respectively, and a single therapy with 100 mg tetracycline or 200 mg clindamycin, had a possibility to clear away B. rodhaini organisms from hosts. However, almost all the treatment groups, had a relapse of the infection within 10 days post treatment or re-treatment. Cured mice by treatment with clindamycin and clindamycin, or clindamycin and tetracycline showed complete resistance against challenge with B. rodhaini, while mice cured by administration of clindamycin at 200 mg or tetracycline at 100 mg showed incomplete resistance to challenge infection. The present data suggest that the two former chemotherapies can induce effective protective immunity (premunization), but the latter two chemotherapies induce incomplete premunization.
